In Brief: Hi-Tech Pharmacal
This article was originally published in The Tan Sheet
Executive Summary
Hi-Tech Pharmacal: Acquires licensing rights to a dietary supplement called Huperzine and its analogs in the U.S., Canada and Europe from the Mayo Clinic in Rochester, Minn. Hi-Tech is planning to conduct clinical trials in the U.S. on Huperzine, a Chinese folk remedy that has been shown to inhibit the enzyme responsible for the breakdown of acetylcholine, a neurotransmitter believed to be important in learning and memory. The natural compound is derived from the club moss Huperzine serrata. "Results suggest" that Huperzine "improves learning and memory in certain patients. However, these suggested results have not been substantiated by clinical trials," Amityville, N.Y.-based Hi-Tech says...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning